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Abstract The identification of relevant protein kinase^protein
substrate partners remains a serious challenge on a genome-wide
scale. The design and synthesis of a photo-activatable nucleotide
reagent to crosslink protein kinases with their substrates is
described in which an azido group is appended to the
Q-phosphoryl and purine moieties of ATP. In the absence of
UV, compounds of this class were shown to act as competitive
inhibitors versus ATP and non-competitive inhibitors versus
peptide substrate for the protein tyrosine kinase Csk, suggesting
that they can form a ternary complex with kinase and protein
substrate. In vitro experiments with protein kinases indicate the
bifunctional reagent can induce covalent protein^protein cross-
linking that is dependent on UV irradiation. That significant
kinase^substrate crosslinking occurs is suggested by the fact that
this crosslinking is competitively inhibited by ATP. The cross-
linked adducts can be readily cleaved by phosphodiesterase which
supports the model for crosslinking and provides a simple method
to deconvolute the linked protein partners. $ 2002 Published
by Elsevier Science B.V. on behalf of the Federation of Euro-
pean Biochemical Societies.
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1. Introduction
The protein kinases are one of the largest protein super-
families in eukaryotic genomes and have attracted consider-
able scienti¢c interest because of their roles in cell physiology
and pathophysiology [1]. For most kinases the true protein
substrates are unknown. Likewise for most phosphorylated
proteins, the protein kinase(s) responsible are not determined.
With roughly 600 protein kinases and thousands of phosphor-
ylated proteins (many on multiple sites) in humans, connect-
ing substrates and kinases represents a complex proteomics
problem that will likely require many independent approaches
to reach resolution [2]. Protein crosslinking reagents have pro-
vided a rich source of information about protein^protein in-
teractions in various biological systems. However, among the
available reagents there are none developed which selectively
link protein kinase^protein substrate pairs. We considered the
possibility that a photo-activatable reagent that was designed
with the ATP moiety as the tether would allow for kinase^
substrate-directed crosslinking (see Fig. 1). Protein kinases
follow ternary complex mechanisms and bind both ATP and
protein substrate in close proximity [3]. In high resolution
structures of protein kinases, the adenine moiety is buried in
the active site of the kinase and the Q-phosphate protrudes
toward the kinase surface where the protein substrate is
thought to bind [4]. Thus protein kinase^protein substrate
crosslinking reagents of the general form in Fig. 1 were pro-
posed. In this report, we describe the design, synthesis, and in
vitro evaluation of a novel protein kinase^protein substrate
crosslinking agent.
2. Materials and methods
2.1. Synthesis of compounds
Compounds 1^3 were prepared from ATP (purchased from Sigma)
and the corresponding amine (aniline, azidoaniline, phenylhydrazine
purchased from Sigma or Aldrich) using a coupling route described
previously [5,6]. For example, the synthesis of 1 was performed as
follows. Adenosine 5P-triphosphate sodium salt (15 mg, 27.3 Wmol)
was dissolved in water (5 ml) and the pH of the solution was brought
to 7 (pH paper) by titrating with sodium hydroxide (1 M). N-Cyclo-
hexyl-NP-(2-morpholiniethyl)carbodiimide methyl-p-toluene sulfonate
(purchased from Aldrich) (382 mg, 0.90 mmol) was added to the
reaction mixture with another 1 ml water. The pH of solution was
brought down to 5.6 with HCl (1 M) and maintained in a pH range
between 5.6 and 5.8 throughout the reaction as determined by pH
paper. Aniline hydrochloride (82 mg, 63.3 mmol) was added to the
solution and the reaction mixture was titrated back to pH 5.6^5.8
with sodium hydroxide (1 M). The reaction was left stirring for an
additional 4 h and then treated with triethylamine to reach pH 8.5.
The mixture was puri¢ed on a DEAE Sephadex-A25 anion exchange
column with pH 8 triethylammonium bicarbonate (TEAB) bu¡er.
Brie£y, a Sephadex DEAE A25 (3 g) was swelled in water, placed
into a column, washed with water (100 ml), 1 M TEAB (100 ml) and
again water (175 ml). A gradient system was used for puri¢cations
(A=water, B=TEAB 1 M) using a £ow rate of 2 ml/min and fraction
sizes of 6 ml at 4‡C; gradient: 0^60 ml, 0% B; 60^260 ml, 0^40% B,
260^360 ml, 40^100% B. Compound 1 was eluted in 61% TEAB (tri-
ethylammonium salt, 14.3 mg, 77%). Compound 4 was synthesized
from ATPQS (purchased from Boehringer) and the commercially
available 4-azido-bromoacetanilide (purchased from Sigma) following
a procedure previously described [3]. Compound 5 was prepared anal-
ogous to compounds 1^3 except that 8-azido-ATP was employed in
place of ATP. Compounds were puri¢ed analogously to compound 1
and then lyophilized to dryness. Each compound showed appropriate
1H nuclear magnetic resonance (NMR), 31P NMR, and electrospray
mass spectrometry (MS) data for structural assignments and purity
(s 90%). Wherever possible, light exposure was limited. These com-
pounds were stored in darkness in frozen aqueous solution at neutral
pH at 380‡C and shown to be stable for several months. Final con-
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centrations were determined from the UV absorbance at 260 nm and
normalized based on the sum of the component acetanilide and ATP-
related moieties. Spectroscopic data for compound 5 : 1H NMR
(D2O) N 8.14 (s, H-2, 1H), 6.96 (dd, H-aromatic, 2H), 6.71 (dd, H-
aromatic, 2H,), 5.87 (d, H-1P, 1H), 4.92 (ddd, H-2P, 1H,), 4.42 (ddd,
H-3P, 1H), 4.15^4.30 (m, H-4P, 1H), 4.01^4.15 (m, H-5P, 2H). 31P
NMR (D2O) N 36.53 (d, PQ ), 37.92 (d, PK), 319.5 (t, PL). Negative
ion EIMS of 5 (calcd. for C16H18N12O12P3 ; M3Hþ, m/z 663).
2.2. Csk kinase assays
Recombinant human Csk was prepared as described previously [7].
Kinetic assays were performed as described using radiolabelled ATP
and the random copolymer peptide substrate 4:1 poly(Glu,Tyr) as
reported previously [7]. In these experiments, radiolabelled ATP is
separated from phosphorylated peptide using 10% SDS^PAGE. Assay
conditions employed ¢xed concentrations of either poly(Glu,Tyr) (200
Wg/ml) or ATP (10 WM) with varying concentration of the other
substrate. Under these conditions, Km for ATP was found to be
V10 WM, Km for poly(Glu,Tyr) V30 Wg/ml, and kcat V25 min31.
The data for each assay were globally ¢t to either linear competitive,
non-competitive, or uncompetitive models using the commercially
available software KinetAsyst II and the selection of ¢t was based
on minimization of standard error and visual inspection. The com-
petitive inhibition plots showed no signi¢cant improvement (less than
two-fold increased standard error) by incorporating a Ki-intercept
term, whereas the non-competitive inhibition plots showed at least a
two-fold improvement by incorporating a Ki-intercept term. The plot-
ted lines displayed in Fig. 3 are calculated based on a global ¢t of the
data in each case.
2.3. Protein crosslinking
Recombinant human Csk (full-length) and recombinant chicken Src
(83^533) were expressed and puri¢ed to near homogeneity as de-
scribed previously [8]. An open 0.6 ml plastic tube (Eppendorf) con-
taining 25 Wl of bu¡ered solution (50 mM Tris^HCl, 4 mM MnCl2,
pH 7.4) at room temperature along with Csk (0.5 WM), Src (5 WM), in
the presence or absence of 5 (25 or 100 WM), was exposed to long
wavelength (broad spectrum centered around 365 nm) UV (Spectro-
line, hand-held lamp) for 45 min. In experiments where ATP was
added, 2 mM (Fig. 4A) or 8 mM (Fig. 4C) ATP (¢nal) was included.
In experiments where phosphodiesterase was added, after UV expo-
sure, 0.029 units of phosphodiesterase I (bovine intestinal mucosa,
Sigma) was employed and the mixture was allowed to stand another
10 min. Reactions were then run out on 10% SDS^PAGE, transferred
to nitrocellulose, and stained with anti-Src or anti-Csk antibodies
(Upstate Biological) and imaged by autoradiography. Monomeric mo-
lecular weights for recombinant Csk and Src are both V50 kDa.
Each experiment was performed at least twice and representative re-
sults are shown.
3. Results and discussion
3.1. E¡ects of Q-substitution of ATP on kinase inhibition
Two potential concerns about the design for a crosslinking
reagent shown in Fig. 1 were: (1) whether substitutions on the
Q-phosphate would prevent or greatly reduce the ability of the
peptide substrate from binding, and (2) whether the azide
moiety on the adenine would prohibit its high a⁄nity binding
with the active site of the protein kinase. To initiate an inves-
tigation of these issues, a series of ATP analogs derivatized in
the Q-position were synthesized (Fig. 2, 1^4) [5,6]. These were
then tested as inhibitors of the protein tyrosine kinase Csk, a
useful protein kinase for enzymatic studies [7]. We were gra-
ti¢ed to ¢nd that these compounds were fairly potent inhib-
itors of kinase activity with Ki 2^6 WM (Fig. 2), slightly lower
than the Km of ATP (10 WM) under these conditions. More-
over, as exempli¢ed by compound 2 (Fig. 3), each of these
compounds showed a linear competitive pattern of inhibition
versus the substrate ATP but proved to be non-competitive
versus the tyrosine peptide substrate (poly(Glu,Tyr)). This
pattern of inhibition suggests that these ATP analogs block
ATP binding but do not prevent appreciably peptide substrate
binding. This is the case because non-competitive inhibitors
can bind to a form of the enzyme that still has the (peptide)
substrate bound. Thus, it is likely that these ATP analogs can
form a ternary complex with protein kinases and protein sub-
strates.
3.2. Protein crosslinking by compound 5
Our next goal was to construct the bifunctional compound
5 which was prepared by condensing 8-azido-ATP and azi-
doaniline. As a Csk inhibitor 5 displayed a Ki that was su⁄-Fig. 1. Strategy for protein kinase^protein substrate crosslinking.
Fig. 2. Synthetic ATP analogs and Ki values for inhibition of pro-
tein tyrosine kinase Csk. Values represent the Ki for a competitive
inhibition model versus ATP at saturating 4:1 poly(Glu,Tyr) con-
centration. The standard errors for these measurements are Q 20%.
See Section 2 for synthetic procedures and kinase assays.
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ciently low to be attractive (7 WM) and was also competitive
versus ATP and non-competitive versus peptide (see Fig. 3).
Consequently, we designed a set of experiments to assess the
possibility of protein photo-crosslinking. We used mixtures
that had the proteins Src, a protein tyrosine kinase that can
phosphorylate itself, and Csk, a protein tyrosine kinase that
can phosphorylate Src [8,9]. The resultant mixtures were then
analyzed by Western blot with an anti-Src antibody (see Fig.
4A). We observed several high molecular weight bands (100
kDa and above) that were likely to be covalent complexes
containing Src based on the fact that the bands were stained
using anti-Src antibody (Fig. 4A, lane 5). That these bands
were actually covalent adducts is likely because a denaturing
gel was used and furthermore, the formation of the adducts
depended on UV light and compound 5 (Fig. 4A, lanes 2 and
3, Fig. 4B, lane 3). Moreover, 8-azido-ATP failed to induce
crosslinking, establishing that the Q-phosphate-azido substitu-
tion was critical (data not shown). Since Csk can phosphory-
late Src and Src can autophosphorylate intermolecularly [8,9],
it should be possible to observe a variety of crosslinked ad-
ducts, consistent with the heterogeneous pattern observed in
Fig. 4. Moreover, it has recently been shown that Csk phos-
phorylation of Src is more e⁄cient when Src is dimerized or
oligomerized [8], suggesting that multiple crosslinked adducts
of these proteins would be favored. In the absence of Csk,
decreased crosslinking is observed (Fig. 4B, compare lanes 1
and 2), consistent with the idea that Csk^Src crosslinks are
present in the mixture. Immunoblotting with anti-Csk anti-
body also suggests the presence of Csk in the crosslinks,
although this experiment is not de¢nitive since some cross-
reactivity between Src protein and anti-Csk is observed
(Fig. 4C).
Having established that compound 5 could induce protein
crosslinking, we next investigated whether the model shown in
Fig. 1 was likely. It would be predicted from this model that
ATP when present in excess could reduce or eliminate cross-
linking by 5 since it would compete for the same nucleotide
binding site. When excess ATP was co-mixed with the cross-
linking reaction, the intensity of the crosslinked Src bands was
signi¢cantly diminished, suggesting that the majority of the
observed crosslinking involved the protein kinase ATP bind-
ing site as designed (Fig. 4A, lane 4; Fig. 4C, lane 2). That the
crosslinking was not completely eliminated by ATP competi-
tion could suggest some non-speci¢c crosslinking involving
other sites on the Src or Csk proteins. If so, enhanced cross-
linking speci¢city might be achievable by reducing crosslink-
ing time, adjusting the geometry of the crosslinker, as well as
by understanding the optimal concentration of protein part-
ners, and these will be addressed in future investigations.
One important step in dissecting the information content
present in the crosslinked complexes is to be able to have a
reliable and gentle method to decompose the complexes into
their constituent protein components. For example, after
crosslinking in a crude cell extract system, it would be advan-
tageous to immunopurify a crosslinked protein of interest and
then separate it away from its unknown partner(s) to aid in
Fig. 3. Pattern of inhibition of Csk by ATP analogs 2 and 5. A,C: Lineweaver^Burk plot of 1/V vs. 1/ATP with varying concentration of com-
pound 2 or 5 shows linear competitive inhibition. B,D: Lineweaver^Burk plot of 1/V vs. 1/poly(Glu,Tyr) with varying concentration of com-
pound 2 or 5 shows linear non-competitive inhibition. Kinase assays and ¢ts were carried out as described in Section 2.
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identi¢cation by MS or N-terminal sequencing. Since the link-
er contains a triphosphate species, it might be possible to
cleave it enzymatically using a non-speci¢c phosphodiesterase
at neutral pH, liberating the component proteins. After the
crosslinked reaction mixture was treated with UV light and 5,
a non-speci¢c phosphodiesterase was added for 10 min prior
to Western blot analysis. Impressively, the bands for cross-
linked Src-containing complexes disappeared, indicating that
the triphosphate linkages in 5 were critical in holding the
crosslinks together (Fig. 4A, lane 1; Fig. 4B, lane 3). This
not only adds chemical proof of the nature of the crosslink
but also provides a simple route to decomposing the crosslink,
which as mentioned will ultimately be helpful in target anal-
ysis. It also suggests that the phosphate diesters are su⁄ciently
exposed to allow access to other enzymes.
4. Conclusions
In summary, these studies describe the synthesis of several
Q-phosphate-tagged nucleotide analogs and explores their po-
tential as kinase inhibitors with the hope of creating protein
kinase^substrate crosslinking reagents. It was shown that
Q-substitution still allows high a⁄nity interaction with a kinase
and likely does not prevent the peptide substrate from binding
to the protein tyrosine kinase Csk. The bifunctional crosslink-
ing agent 5 led to easily observable protein crosslinking that
was likely to be covalent. Competition with ATP suggests that
much of the protein crosslinking was nucleotide site-mediated
validating the design. A simple enzymatic method was shown
to e⁄ciently cleave the linkages. It is expected that immuno-
precipitation or other a⁄nity puri¢cation procedures when
combined with this crosslinking method will allow exploita-
tion of the reagent in cell lysates to identify novel kinase^
substrate interactions. Ultimately, replacement of the phos-
phates, to allow cell permeability, and the adenosine with
high a⁄nity nucleoside analogs may also increase the speci-
¢city and utility of the approach. We believe however that the
approach described here provides a new direction in the pro-
teomics analysis of protein kinase^substrate interactions.
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